Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 38 filings·Updated 24 Aug 2026
Showing 10 of 38 filings.
24 Aug 20261 filing
Company UpdateNewspaper Publication

We are enclosing herewith copy of newspaper advertisement w.r.t Notice and e-voting for Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M through video conferening, ....

Filed 12:11View Source
22 Aug 20262 filings
Corp. ActionBook Closure

Clinitech Lab: Book closure for 16th AGM Sep 18, 2025 - Sep 24, 2026; e-voting Sep 21-23, 2026

Key dates

  • Book closure: Sep 18, 2025 to Sep 24, 2026 (both days inclusive) for 16th AGM.
  • Purpose: 16th Annual General Meeting.
  • E-voting cut-off: Sep 17, 2026.
  • E-voting period: Sep 21, 2026 09:00 IST to Sep 23, 2026 17:00 IST.
  • AGM date: Sep 24, 2026 at 11:30 IST via VC/OAVM.
Filed 17:38View Source
OthersReg. 34 (1) Annual Report

Clinitech Laboratory Limited FY2025-26: Revenue growth, PAT rise, two new subsidiaries, IPO proceeds utilised; no dividend

Financials (Standalone)

  • Standalone revenue from operations reached 947.50 lakhs.
  • Total standalone revenue stood at 966.31 lakhs.
  • Net profit after tax was 42.25 lakhs.
  • Basic earnings per share: 1.85.
  • Dividend declared for FY2025-26: none.
  • Cash and cash equivalents: 206.46 lakhs.

Subsidiaries & IPO

  • Two subsidiaries formed in FY25-26: Medicarenx and Analog IVD.
  • Each subsidiary is 60% owned.
  • No material subsidiaries as of 31 Mar 2026.
  • IPO proceeds raised: 578.30 lakhs; utilized 528.30; unutilized 50.00.

Capital structure & liquidity

  • Standalone long-term borrowings: 35.76; consolidated 53.75.
  • Current ratio: 7.04x.
  • Trade payables: 39.95 standalone; 48.35 consolidated.
  • Cash and cash equivalents: 206.46 standalone; 211.22 consolidated.
  • Issued share capital: 228.24 lakhs.

Governance

  • Board: 6 directors; 2 executive, 4 non-executive.
  • Independent directors: 3; 10 board meetings in FY25-26.
  • Audit Committee: 3 independent directors; 9 meetings.
  • Secretarial audit: Deep Shukla & Associates.

Management & risk

  • Indian diagnostic sector shows growth through automation and digital labs.
  • Risks include regulatory changes, pricing, competition, and cybersecurity.
  • Management aims to expand services via subsidiaries and upgrades.
  • Digital health adoption supports long-term diagnostic growth.

Audits & compliance

  • Statutory auditors: Kale Malde & Co.; Internal auditors: Kalpesh Khatri & Associates.
  • Secretarial auditor: Deep Shukla & Associates; no adverse auditor remarks.

AGM & notices

  • 16th AGM to be held Sep 24, 2026 via VC/OAVM.
  • Notice and annual report disseminated electronically; available to shareholders.
Filed 17:26View Source
17 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Clinitech approves director reappointment, AGM notice, book closure, and scrutineer for 16th AGM

Key board decisions

  • Approved reappointment of director retiring by rotation.
  • Approved Board's report for FY 2025-26 and annexures.
  • Approved notice for the 16th AGM with date, time, venue.
  • Finalized book-closure dates for the forthcoming AGM.
  • Appointed Mr. Deep Shukla, Practising Company Secretary, as Scrutinizer for voting.
Filed 12:11View Source
12 Aug 20261 filing
Board Meeting

Clinitech Lab board to meet Aug 17, 2026 via video; approvals include AGM notice and director appointment

Meeting Details

  • Date: August 17, 2026
  • Time: 11:30 AM IST
  • Mode: Video conferencing

Key Agenda Items

  • To consider and approve appointment of a director retiring by rotation.
  • To approve the Board's report for FY 2025-26, including annexures.
  • To consider and approve the notice for 16th AGM and book-closure dates.
  • To finalize the appointment of Mr. Deep Shukla as Scrutinizer for voting.

Other Notes

  • Notice confirms August 17, 2026 board meeting via video conferencing.
Filed 13:30View Source
7 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5): No rematerialisation requests; all shares in demat form

Regulation 74(5) status

  • RTA confirms Regulation 74(5) not applicable; entire holding dematerialised, no rematerialisation requests in quarter ended 30 June 2026.
Filed 17:53View Source
27 Apr 20261 filing
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Filed 11:32View Source
15 Apr 20261 filing
Company UpdateReg.24(A)-Annual Secretarial Compliance

Undertaking for non-applicablity of Annual Secretarial compliance report under Reg 24A of SEBI (LODR) since our company is SME listed entity.

Filed 16:21View Source
9 Apr 20261 filing
Company UpdateGeneral

General update under Reg 30 of SEBI (LODR) Regulations for change in market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited w.e.f April 10, 2026 as ....

Filed 15:44View Source
30 Mar 20261 filing
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Nayak & PACs

Filed 17:57View Source
Showing 10 of 38 filings